Go to content

Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:

  1. Package advice for the lock procedure drug betibeglogene autotemcel (Zynteglo®)

    The National Health Care Institute has completed its assessment whether betibeglogene autotemcel (Zynteglo®) can be included in ...

    Report | 21-07-2021

  2. Package advice on avelumab (Bavencio®) for treating urothelial cell carcinoma

    Zorginstituut Nederland has completed its assessment whether avelumab (Bavencio®) can be included in the insured package. ...

    Report | 21-07-2021

  3. Package advice on entrectinib (Rozlytrek®) for the treatment of ROS1 fusion-positive advanced non-small cell lung cancer

    Zorginstituut Nederland has completed its assessment whether entrectinib (Rozlytrek®) can be included in the insured package. The ...

    Report | 21-07-2021

  4. GVS advice for cladribine (Mavenclad®) – extension of further conditions

    The National Health Care Institute has completed its reassessment whether the further conditions of cladribine (Mavenclad®) could ...

    Report | 05-07-2021

  5. GVS assessment of calcifediol (Hidroferol®)

    Zorginstituut Nederland has completed its assessment whether calcifediol (Hidroferol®) is interchangeable with a medicine already ...

    Report | 01-07-2021

  6. Package advice niraparib (Zejula®)

    Zorginstituut Nederland has completed its assessment whether niraparib (Zejula®) can be included in the insured package. ...

    Report | 24-06-2021

  7. GVS advice SGLT-2 inhibitors

    The National Health Care Institute has completed its assessment the further conditions of SGLT-2 inhibitors canagliflozin ...

    Report | 22-06-2021

  8. GVS advice RZV (Shingrix®) for the prevention of herpes zoster and related post-herpetic neuralgia

    Zorginstituut Nederland has completed its assessment whether the recombinant herpes zoster vaccine with adjuvant (RZV, Shingrix®) ...

    Report | 14-06-2021

  9. GVS advice onosilodrostat (Isturisa®) for the treatment of endogenous Cushing syndrome

    The National Health Care Institute advises the Minister to include osilodrostat on List 1A in cluster 0V04CDAO V. Osilodrostat ...

    Report | 14-06-2021

  10. GVS advice avatrombopag (Doptelet®) for the treatment of thrombocytopenia

    The National Health Care Institute has completed its assessment whether avatrombopag (Doptelet®) is interchangeable with a ...

    Report | 08-06-2021

Go to